Protein expression profiles in pediatric multiple sclerosis: Potential biomarkers

Multiple Sclerosis

Volumn 15, Issue 4, 2009, Pages 455-464

  Rithidech, K Noy ^a   Honikel, L ^a   Milazzo, M ^a   Madigan, D ^a   Troxell, R ^a   Krupp, L B ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

2D gel electrophoresis; Blood; Mass spectrometry; Multiple sclerosis; Proteomics

Indexed keywords

ALPHA 1 BETA GLYCOPROTEIN; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; CLUSTERIN; COMPLEMENT FACTOR I; GELSOLIN; GLYCOPROTEIN; HEMOPEXIN; KININOGEN; OROSOMUCOID; PREALBUMIN; SERUM AMYLOID P; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD HEALTH; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADOLESCENT; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PROTEOMICS; YOUNG ADULT;

EID: 63449122537     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508100047     Document Type: Article

References (37)

1. Boiko, A, Vorobeychik, G, Paty, D, Devonshire, V, Sadovnick, D. Early onset multiple sclerosis: A longitudinal study. Neurology 2002; 59: 1006-1010.
2. Ness, JM, Chabas, D, Sadovnick, AD, Pohl, D, Banwell, B, Weinstock-Guttman, B. Clinical features of children and adolescents with multiple sclerosis. Neurology 2007; 68: S37-S45.
3. Schwarz, S, Mohr, A, Knauth, M, Wildemann, B, Storch-Hagenlocher, B. Acute disseminated encephalomyelitis: A follow-up study of 40 adult patients. Neurology 2001; 56: 1313-1318.
4. Banwell, B, Krupp, L, Kennedy, J, et al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol 2007; 6: 773-781.
5. Ghezzi, A, Pozzilli, C, Liguori, M, et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002; 8: 115-118.
6. Martin, R, Leppert, D. A plea for "omics" research in complex diseases such as multiple sclerosis - a change of mind is needed. J Neurol Sci 2004; 222: 3-5.
7. Gygi, SP, Rochon, Y, Franza, BR, Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-1730.
8. Celis, JE, Kruhoffer, M, Gromova, I, et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 2000; 480: 2-16.
9. Lian, Z, Wang, L, Yamaga, S, et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood 2001; 98: 513-524.
10. Oberemm, A, Onyon, L, Gundert-Remy, U. How can toxicogenomics inform risk assessment. Toxicol Appl Pharmacol 2005; 207: 592-598.
11. Rodland, KD. Proteomics and cancer diagnosis: The potential of mass spectrometry. Clin Biochem 2004; 37: 579-583.
12. Goldknopf, IL. Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics 2008; 5: 1-8.
13. Kim, JK, Mastronardi, FG, Wood, DD, Lubman, DM, Zand, R, Moscarello, MA. Multiple Sclerosis: An important role for post-translational modifications of MBP in pathogenesis. Mol Cell Proteomics 2003; 2: 453-462.
14. Krupp, LB, Banwell, B, Tenembaum, S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68: S7-S12.
15. Rithidech, KN, Honikel, L, Simon, SR. Radiation leukemogenesis: A proteomic approach. Exp Hematol 2007; 35: 117-124.
16. Anderson, NL, Polanski, M, Pieper, R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3: 311-326.
17. Kermode, AG, Thompson, AJ, Tofts, P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multipke sclerosis: Pathogentic and clinical implications. Brain 1990; 113: 1477-1489.
18. Gygi, SP, Aebersold, R. Mass spectrometry and proteomics. Curr Opin Chem Biol 2000; 4: 489-494.
19. Kinter, M, Sherman, NE. Protein sequencing and identification using tandem mass spectrometry. New York: Wiley Interscience; 2002 [Multi Probe II HT Ex, Perkin Elmer].
20. Unlu, M, Morgan, ME, Minden, JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-2077.
21. Dumont, D, Noben, JP, Raus, J, Stinissen, P, Robben, J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004; 4: 2117-2124.
22. Hammack, BN, Fung, KY, Hunsucker, SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10: 245-260.
23. Lehmensiek, V, Sussmuth, SD, Tauscher, G, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840-849.
24. OConnor, KC, Roy, SM, Becker, CH, Hafler, DA, Kantor, AB. Comprehensive phenotyping in multiple sclerosis: Discovery based proteomics and the current understanding of putative biomarkers. Dis Markers 2006; 22: 213-225.
25. Agnello, D, Carvelli, L, Muzio, V, et al. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: Relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol 2000; 109: 105-111.
26. Chrostek, L, Cylwik, B, Krawiec, A, Korcz, W, Szmitkowski, M. Relationship between serum sialic acid and sialylated glycoproteins in alcoholics. Alcohol Alcohol 2007; 42: 588-592.
27. Harrington, MG, Aebersold, R, Martin, BM, Merril, CR, Hood, L. Identification of a brain-specific human cerebrospinal fluid glycoprotein, beta-trace protein. Appl Theor Electrophor 1993; 3: 229-234.
28. Adam, P, Sobek, O, Taborsky, L, Hildebrand, T, Tutterova, O, Zacek, P. CSF and serum orosomucoid ([alpha]-1-acid glycoprotein) in patients with multiple sclerosis: A comparison among particular subgroups of MS patients. Clin Chim Acta 2003; 334: 107-110.
29. Wong, C-T, Tsoi, W-F, Saha, N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 1996; 22: 165-171.
30. Chandler, S, Miller, KM, Clements, JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol 1997; 72: 155-161.
31. Yong, VW, Power, C, Forsyth, P, Edwards, DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-511.
32. Lee, MA, Palace, J, Stabler, G, Ford, J, Gearing, A, Miller, K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: A longitudinal clinical and MRI study. Brain 1999; 122: 191-197.
33. Colman, RW, Sartor, RB, Adam, AA, DeLa Cadena, RA, Stadnicki, A. The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol 1998; 16: 365-384.
34. Prat, A, Biernacki, K, Saroli, T, et al. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: Correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol 2005; 62: 795-800.
35. Munger, KL, Levin, LI, Hollis, BW, Howard, NS, Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838.
36. White, P, Cooke, N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.
37. Kim, H-J, DiBernardo, AB, Sloane, JA, et al. WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination. J Neurosci 2006; 26: 5849-5859.